The fourth ustekinumab biosimilar to receive FDA approval is Otulfi™, which was developed by Formycon AG and will be marketed by its partner Fresenius Kabi. Originally designated FYB202, the biosimilar’s nonproprietary name is ustekinumab-aauz. It is Fresenius Kabi’s fourth biosimilar approval in the US. The FDA approval was based on the totality of evidence, including … Continue reading Partners Fresenius Kabi and Formycon Get FDA Approval for Their Ustekinumab Biosimilar